8月28日 - ** 德国制药公司BioNTech（BNTX.O 22UAy.DE）在美上市的股票下跌8.6%，收于101.84美元
** 同为mRNA制药商的Moderna（MRNA.O）股价下跌5.2%，收于135.37美元
** 该公司终止了针对已接受手术的高危结直肠癌患者开展的、其实验性个性化mRNA疗法autogene cevumeran的中期临床试验
** 该公司表示，独立监查员发现接受该治疗的患者与采取密切观察策略的患者在总生存期方面存在数值上的不平衡，并得出结论认为继续进行该试验不太可能改变结果
** 虽未披露哪一组患者的生存情况更差，但表示未发现新的安全性问题
** 表示另一项针对胰腺癌、测试该疗法与其他抗癌药物联合使用的试验将按计划继续进行；该疗法正与罗氏旗下 ROPC.S 基因泰克（Genentech）部门联合开发
** 算上本交易日的变动，BNTX今年以来累计上涨7.9%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.